Sucralfate

drug-information.ru

|Sucralfate

Drugs search, click the first letter of a drug name:


| A | B | C | D | E | F | G | H | I | J | K | L | M | N | O | P | Q | R | S | T | U | V | W | X | Y | Z | 1 | 2 | 3 | 4 | 5 | 6 | 8 | 9  Home

Sucralfate

Dosage Form: Tablets

Sucralfate Description

Sucralfate is an α-D-glucopyranoside,β-D-fructofuranosyl-,octakis (hydrogen sulfate), aluminum complex.

R=SO3[Al2(OH)5·(H2O)2]

Tablets for oral administration contain 1 gram of Sucralfate.

Inactive Ingredients

Corn Starch, Magnesium Stearate and Microcrystalline Cellulose.

Therapeutic Category

antiulcer.

Sucralfate - Clinical Pharmacology

Sucralfate is only minimally absorbed from the gastrointestinal tract. The small amounts of the sulfated disaccharide that are absorbed are excreted primarily in the urine.

Although the mechanism of Sucralfate’s ability to accelerate healing of duodenal ulcers remains to be fully defined, it is known that it exerts its effect through a local, rather than systemic, action. The following observations also appear pertinent:

  1. Studies in human subjects and with animal models of ulcer disease have shown that Sucralfate forms an ulcer-adherent complex with proteinaceous exudate at the ulcer site.
  2. In vitro, a Sucralfate-albumin film provides a barrier to diffusion of hydrogen ions.
  3. In human subjects, Sucralfate given in doses recommended for ulcer therapy inhibits pepsin activity in gastric juice by 32%.
  4. In vitro, Sucralfate absorbs bile salts.

These observations suggest that Sucralfate’s antiulcer activity is the result of formation of an ulcer-adherent complex that covers the ulcer site and protects it against further attack by acid, pepsin, and bile salts. There are approximately 14-16 mEq of acid-neutralizing capacity per 1-gram dose of Sucralfate.

Clinical Trials

Acute Duodenal Ulcer

Over 600 patients have participated in well-controlled clinical trials worldwide. Multicenter trials conducted in the United States, both of them placebo-controlled studies with endoscopic evaluation at two and four weeks, showed:

STUDY 1    
Treatment Groups Ulcer Healing/No. Patients
  2 wk 4 wk (Overall)
Sucralfate 37/105 (35.2%) 82/109 (75.2%)
Placebo 26/106 (24.5%) 68/107 (63.6%)
STUDY 2
Treatment Groups Ulcer Healing/No. Patients
2 wk 4 wk (Overall)
Sucralfate 8/24 (33%) 22/24 (92%)
Placebo 4/31 (13%) 18/31 (58%)

The Sucralfate-placebo differences were statistically significant in both studies at four weeks but not at two weeks. The poorer result in the first study may have occurred because Sucralfate was given two hours after meals and at bedtime rather than one hour before meals and at bedtime, the regimen used in international studies and in the second United States study. In addition, in the first study liquid antacid was utilized as needed, whereas in the second study antacid tablets were used.

Maintenance Therapy After Healing of Duodenal Ulcer

Two double-blind randomized placebo-controlled U.S. multicenter trials have demonstrated that Sucralfate (1 g bid) is effective as maintenance therapy following healing of duodenal ulcers.

In one study, endoscopies were performed monthly for 4 months. Of the 254 patients who enrolled, 239 were analyzed in the intention-to-treat life table analysis presented below.

Duodenal Ulcer Recurrence Rate (%)

*p<0.05

**p<0.01

Months of Therapy
Drug N 1 2 3 4
Sucralfate 122 20* 30* 38** 42**
Placebo 117 33 46 55 63

Prn antacids were not permitted in this study.

In the other study, scheduled endoscopies were performed at 6 and 12 months, but for cause, endoscopies were permitted as symptoms dictated. Median symptom scores between the Sucralfate and placebo groups were not significantly different. A life table intention-to-treat analysis for the 94 patients enrolled in the trial had the following results:

Duodenal Ulcer Recurrence Rate (%)

*p<0.002

Drug N 6 Months 12 Months
Sucralfate 48 19* 27*
Placebo 46 54 65

Prn antacids were permitted in this study.

Data from placebo-controlled studies longer than 1 year are not available.

Indications and Usage for Sucralfate

Sucralfate is indicated in:

  • Short-term treatment (up to 8 weeks) of active duodenal ulcer. While healing with Sucralfate may occur during the first week or two, treatment should be continued for 4 to 8 weeks unless healing has been demonstrated by x-ray or endoscopic examination.
  • Maintenance therapy for duodenal ulcer patients at reduced dosage after healing of acute ulcers.

Contraindications

There are no known contraindications to the use of Sucralfate.

Precautions

Duodenal ulcer is a chronic, recurrent disease. While short-term treatment with Sucralfate can result in complete healing of the ulcer, a successful course of treatment with Sucralfate should not be expected to alter the posthealing frequency or severity of duodenal ulceration.

Special Populations

Chronic Renal Failure and Dialysis Patients

When Sucralfate is administered orally, small amounts of aluminum are absorbed from the gastrointestinal tract. Concomitant use of Sucralfate with other products that contain aluminum, such as aluminum-containing antacids, may increase the total body burden of aluminum. Patients with normal renal function receiving the recommended doses of Sucralfate and aluminum-containing products adequately excrete aluminum in the urine. Patients with chronic renal failure or those receiving dialysis have impaired excretion of absorbed aluminum. In addition, aluminum does not cross dialysis membranes because it is bound to albumin and transferrin plasma proteins. Aluminum accumulation and toxicity (aluminum osteodystrophy, osteomalacia, encephalopathy) have been described in patients with renal impairment. Sucralfate should be used with caution in patients with chronic renal failure.

Drug Interactions

Some studies have shown that simultaneous Sucralfate administration in healthy volunteers reduced the extent of absorption (bioavailability) of single doses of the following: cimetidine, digoxin, fluoroquinolone antibiotics, ketoconazole, 1-thyroxine, phenytoin, quinidine, ranitidine, tetracycline, and theophylline. Subtherapeutic prothrombin times with concomitant warfarin and Sucralfate therapy have been reported in spontaneous and published case reports. However, two clinical studies have demonstrated no change in either serum warfarin concentration or prothrombin time with the addition of Sucralfate to chronic warfarin therapy.

The mechanism of these interactions appears to be nonsystemic in nature, presumably resulting from Sucralfate binding to the concomitant agent in the gastrointestinal tract. In all cases studied to date (cimetidine, ciprofloxacin, digoxin, ranitidine, and warfarin), dosing the concomitant medication 2 hours before Sucralfate eliminated the interaction. Because of the potential of Sucralfate to alter the absorption of some drugs, Sucralfate should be administered separately from other drugs when alterations in bioavailability are felt to be critical. In these cases, patients should be monitored appropriately.

Carcinogenesis, Mutagenesis, Impairment of Fertility

Chronic oral toxicity studies of 24 months’ duration were conducted in mice and rats at doses up to 1 g/kg (12 times the human dose). There was no evidence of drug-related tumorigenicity. A reproduction study in rats at doses up to 38 times the human dose did not reveal any indication of fertility impairment. Mutagenicity studies were not conducted.

Pregnancy

Teratogenic Effects

Pregnancy Category B

Teratogenicity studies have been performed in mice, rats, and rabbits at doses up to 50 times the human dose and have revealed no evidence of harm to the fetus due to Sucralfate. There are, however, no adequate and well-controlled studies in pregnant women. Because animal reproduction studies are not always predictive of human response, this drug should be used during pregnancy only if clearly needed.

Nursing Mothers

It is not known whether this drug is excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised when Sucralfate is administered to a nursing woman.

Pediatric Use

Safety and effectiveness in children have not been established.

Adverse Reactions

Adverse reactions to Sucralfate in clinical trials were minor and only rarely led to discontinuation of the drug. In studies involving over 2,700 patients treated with Sucralfate tablets, adverse effects were reported in 129 (4.7%).

Constipation was the most frequent complaint (2%). Other adverse effects reported in less than 0.5% of the patients are listed below by body system:

Gastrointestinal

diarrhea, nausea, vomiting, gastric discomfort, indigestion, flatulence, dry mouth

Dermatological

pruritus, rash

Nervous System

dizziness, insomnia, sleepiness, vertigo

Other

back pain, headache

Postmarketing reports of hypersensitivity reactions, including urticaria (hives), angioedema, respiratory difficulty, rhinitis, laryngospasm, and facial swelling have been reported in patients receiving Sucralfate tablets. Similar events were reported with Sucralfate suspension. However, a causal relationship has not been established.

Bezoars have been reported in patients treated with Sucralfate. The majority of patients had underlying medical conditions that may predispose to bezoar formation (such as delayed gastric emptying) or were receiving concomitant enteral tube feedings.

Inadvertent injection of insoluble Sucralfate and its insoluble excipients has led to fatal complications, including pulmonary and cerebral emboli. Sucralfate is not intended for intravenous administration.

Overdosage

Due to limited experience in humans with overdosage of Sucralfate, no specific treatment recommendations can be given. Acute oral toxicity studies in animals, however, using doses up to 12 g/kg body weight, could not find a lethal dose. Sucralfate is only minimally absorbed from the gastrointestinal tract. Risks associated with acute overdosage should, therefore, be minimal. In rare reports describing Sucralfate overdose, most patients remained asymptomatic. Those few reports where adverse events were described included symptoms of dyspepsia, abdominal pain, nausea, and vomiting.

Sucralfate Dosage and Administration

Active Duodenal Ulcer

The recommended adult oral dosage for duodenal ulcer is 1 gram four times a day on an empty stomach.

Antacids may be prescribed as needed for relief of pain but should not be taken within one-half hour before or after Sucralfate.

While healing with Sucralfate may occur during the first week or two, treatment should be continued for 4 to 8 weeks unless healing has been demonstrated by x-ray or endoscopic examination.

Maintenance Therapy

The recommended adult oral dosage is 1 gram twice a day.

How is Sucralfate Supplied

Sucralfate Tablets, USP are supplied as white, single-scored, capsule-shaped tablets containing 1 gram of Sucralfate. Available in bottles of 100 and 500. Tablets are debossed “BIOCRAFT” on one side and “105” twice on the scored side.

Dispense in a tight container as defined in the USP/NF.

Store at controlled room temperature, between 20° and 25° C (68° and 77° F) (see USP).

Manufactured By:

TEVA PHARMACEUTICALS USA

Sellersville, PA 18960

Rev. D 9/2003


Sucralfate (Sucralfate)
PRODUCT INFO
Product Code 0093-2210 Dosage Form TABLET
Route Of Administration ORAL DEA Schedule
INGREDIENTS
Name (Active Moiety) Type Strength
Sucralfate (Sucralfate) Active 1 GRAM  In 1 TABLET
corn starch Inactive  
magnesium stearate Inactive  
microcrystalline cellulose Inactive  
IMPRINT INFORMATION
Characteristic Appearance Characteristic Appearance
Color WHITE Score 2
Shape OVAL (capsule shaped) Symbol false
Imprint Code BIOCRAFT;105;105 Coating false
Size 19mm
PACKAGING
# NDC Package Description Multilevel Packaging
1 0093-2210-01 100 TABLET In 1 BOTTLE None
2 0093-2210-05 500 TABLET In 1 BOTTLE None

Revised: 11/2006





Where can I get more information about Sucralfate ? We recommend to use www.Drugs.com

Typical mistypes for Sucralfate
aucralfate, zucralfate, xucralfate, ducralfate, eucralfate, wucralfate, sycralfate, shcralfate, sjcralfate, sicralfate, s8cralfate, s7cralfate, suxralfate, suvralfate, sufralfate, sudralfate, sucealfate, sucdalfate, sucfalfate, suctalfate, suc5alfate, suc4alfate, sucrzlfate, sucrslfate, sucrwlfate, sucrqlfate, sucrakfate, sucrapfate, sucraofate, sucraldate, sucralcate, sucralvate, sucralgate, sucraltate, sucralrate, sucralfzte, sucralfste, sucralfwte, sucralfqte, sucralfare, sucralfafe, sucralfage, sucralfaye, sucralfa6e, sucralfa5e, sucralfatw, sucralfats, sucralfatd, sucralfatr, sucralfat4, sucralfat3, ucralfate, scralfate, suralfate, sucalfate, sucrlfate, sucrafate, sucralate, sucralfte, sucralfae, sucralfat, uscralfate, scuralfate, surcalfate, sucarlfate, sucrlafate, sucraflate, sucralafte, sucralftae, sucralfaet, ssucralfate, suucralfate, succralfate, sucrralfate, sucraalfate, sucrallfate, sucralffate, sucralfaate, sucralfatte, sucralfatee, etc.



© Copyright by drug-information.ru 2001-2019. All rights reserved